Status:
COMPLETED
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Community-Acquired Infections
Bacterial Pneumonia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.
Eligibility Criteria
Inclusion
- Male and female subjects ≥ 18 years of age and in Bulgaria only ≤ 70 years of age
- Subjects hospitalized with CAP with a severity that requires IV antibiotic treatment for at least 7 days
- The presence of fever (within 24 hours before randomization)
Exclusion
- Any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed (eg, life expectancy \<30 days).
- Hospitalization within 14 days before the onset of symptoms.
- Residence in a long-term care facility or nursing home ≥14 days before the onset of symptoms.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
434 Patients enrolled
Trial Details
Trial ID
NCT00081575
Start Date
January 1 2004
End Date
March 1 2005
Last Update
February 8 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.